Jun 10, 2026
Onco-Innovations has begun scaling production of A83B4C63, the API in its lead cancer drug ONC010, to kilogram quantities at Dalton Pharma Services' Toronto facility to support IND-enabling studies. The company's subsidiary Inka Health signed AI research agreements with AstraZeneca and GlaxoSmithKline, and plans a first-in-human study in 2026 pending a pre-IND meeting with the FDA.
Jun 09, 2026
The Australian government announced an additional $387.4 million for CSIRO over four years and $12.7 million for eight quantum technology projects under the Critical Technologies Challenge Program, part of its broader National Quantum Strategy commitment.
Jun 09, 2026
NASA announced the four-member Artemis III crew, who will test lunar lander rendezvous and docking operations ahead of the 2028 moon landing attempt. The mission faces uncertainty as Blue Origin recovers from a launch pad explosion and SpaceX continues developing its lander system. Space medicine experts note that deeper missions will require astronauts to manage medical care independently without Earth support.
Jun 09, 2026
BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven analytics into an ADC development program. The company also revealed six abstracts will be presented at the EHA 2026 Congress in Stockholm. The research showcases integrated multiomics and predictive modeling for blood cancer treatment optimization.
Jun 04, 2026
iPSC-derived NK cell therapies are advancing rapidly with 12+ companies developing 15+ pipeline drugs. Japan's PMDA approved an iPS cell-derived NK cell therapy for mediastinal germ cell tumors in December 2025. Key clinical milestones include Century Therapeutics' CNTY-101 continuing in a Phase I/II trial.
Jun 02, 2026
Rural cancer death rates are highest while big-city rates are lowest, a study of 28 million deaths found. However, separate research shows rural lung and colon cancer patients treated locally had similar outcomes to those at urban centers.
Jun 02, 2026
Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.
May 31, 2026
The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.
May 26, 2026
The global radiopharmaceuticals market is projected to reach $12.8B–$21.8B by 2033–2036, driven by cancer therapy demand. Oncology accounts for over 50% of applications, Technetium-99m dominates radioisotopes, and Asia-Pacific leads growth.
May 24, 2026
Maharashtra will add immunotherapy and PET scans to its state health scheme and open 27 new cancer centres. Separately, the ICMR has issued national guidelines for lung cancer treatment including immunotherapy protocols, as MPs push for expanded access.
May 23, 2026
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
May 20, 2026
Research and Markets added two cell and gene therapy publications, including a tools and reagents market report forecasting growth from $12 billion in 2025 to $19.8 billion by 2030. The reports track approvals, financing, deals, and manufacturing developments.
May 20, 2026
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
May 20, 2026
An experimental study found remote ischemic conditioning protected the heart during anthracycline treatment in tumor-bearing mice without reducing antitumor efficacy. The work supports the ongoing RESILIENCE clinical trial in cancer patients.
May 19, 2026
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
May 15, 2026
Only 17.7% of pediatric anticancer drugs advance to phase 3 trials, and just 12% earn FDA approval within 10 years, compared to 38.7% for adult drugs. The pace of pediatric approvals has accelerated recently, but funding and market size constraints remain.
May 14, 2026
Biotech M&A is shifting toward late-stage CNS and oncology assets with human clinical validation. Oncotelic Therapeutics said it advanced global IP protection for OT-101 and CNS drug delivery.
May 13, 2026
Microgravity drug research is expanding from ISS crystal studies to commercial manufacturing efforts. New experiments and a Varda-United Therapeutics collaboration target improved drug stability, delivery and production.
May 07, 2026
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
May 05, 2026
Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.
